Clinical Trial Update: Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating intrathecal trastuzumab for leptomeningeal metastases in HER2-positive breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Leptomeningeal Metastases

Drugs mentioned

• Trastuzumab (trastuzumab)

Snippet

Sponsor: Northwestern University | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-05-28